Deanna J. Attai, MD, surgeon, president, Center For Breast Care, Burbank, CA, discusses patients' perception of breast cancer risk.
Deanna J. Attai, MD, surgeon, president, Center For Breast Care, Burbank, CA, discusses patients' perception of breast cancer risk.
As there is a plethora of information about breast cancer awareness and early detection, Attai says, many women do not have a good sense of their true risk. A study presented at the 2013 Breast Cancer Symposium showed that in over 9,000 women, 40-45% either underestimated or overestimated their risk by at least 10%.
If a patient is at high risk but believes that she is at lower risk, Attai says, she may be less likely to see the need to take tamoxifen for risk reduction or may not see the need for lifestyle changes. If a patient is at low risk for breast cancer, she may believe she needs prophylactic mastectomies for no good medical reason.
It is important for all of a patient's physicians to give them an idea of what is truly their risk.
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
May 16th 2024During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More